Land: Den Europæiske Union
Sprog: engelsk
Kilde: EMA (European Medicines Agency)
human normal immunoglobulin (IVIg)
Takeda Manufacturing Austria AG
J06BA02
human normal immunoglobulin
Immune sera and immunoglobulins,
Purpura, Thrombocytopenic, Idiopathic; Bone Marrow Transplantation; Immunologic Deficiency Syndromes; Guillain-Barre Syndrome; Mucocutaneous Lymph Node Syndrome
Replacement therapy in adults, and children and adolescents (0-18 years) in:primary immunodeficiency syndromes with impaired antibody production;hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed;hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who have failed to respond to pneumococcal immunisation;hypogammaglobulinaemia in patients after allogeneic haematopoietic-stem-cell transplantation (HSCT);congenital AIDS and recurrent bacterial infections.Immunomodulation in adults, and children and adolescents (0-18 years) in:primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count;Guillain Barré syndrome;Kawasaki disease;multifocal motor neuropathy (MMN).
Revision: 26
Authorised
2006-01-18
28 B. PACKAGE LEAFLET 29 PACKAGE LEAFLET: INFORMATION FOR THE USER KIOVIG 100 MG/ML SOLUTION FOR INFUSION human normal immunoglobulin READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor, pharmacist or nurse. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What KIOVIG is and what it is used for 2. What you need to know before you use KIOVIG 3. How to use KIOVIG 4. Possible side effects 5. How to store KIOVIG 6. Contents of the pack and other information 1. WHAT KIOVIG IS AND WHAT IT IS USED FOR KIOVIG belongs to a class of medications called immunoglobulins. These medicines contain human antibodies, which are also present in your blood. Antibodies help your body to fight infections. Medicines like KIOVIG are used in patients who do not have enough antibodies in their blood and tend to get frequent infections. They can also be used in patients who need additional antibodies for the cure of certain inflammatory disorders (autoimmune diseases). KIOVIG IS USED FOR TREATMENT OF PATIENTS WHO DO NOT HAVE SUFFICIENT ANTIBODIES (REPLACEMENT THERAPY). THERE ARE TWO GROUPS: 1. Patients with inborn lack of antibody production (primary immunodeficiency syndromes). 2. Patients with secondary immunodeficiencies (SID) who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either PROVEN SPECIFIC ANTIBODY FAILURE (PSAF)* or serum IgG level of <4 g/l. *PSAF = failure to mount at least a 2-fold rise in IgG antibody titre to pneumococcal polysaccharide and polypeptide antigen vaccines TREATMENT OF PATIENTS WITH CERTAIN INFLAMMATORY DISORDERS Læs hele dokumentet
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT KIOVIG 100 mg/ml solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Human normal immunoglobulin (IVIg) One ml contains: Human normal immunoglobulin ……………100 mg (purity of at least 98% IgG) Each vial of 10 ml contains: 1 g of human normal immunoglobulin Each vial of 25 ml contains: 2.5 g of human normal immunoglobulin Each vial of 50 ml contains: 5 g of human normal immunoglobulin Each vial of 100 ml contains: 10 g of human normal immunoglobulin Each vial of 200 ml contains: 20 g of human normal immunoglobulin Each vial of 300 ml contains: 30 g of human normal immunoglobulin Distribution of IgG subclasses (approx. values): IgG1 ≥56.9% IgG2 ≥26.6% IgG3 ≥3.4% IgG4 ≥1.7% The maximum IgA content is 140 micrograms/ml. Produced from the plasma of human donors. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for infusion The solution is clear or slightly opalescent and colourless or pale yellow. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Replacement therapy in adults, and children and adolescents (0-18 years) in: Primary immunodeficiency syndromes (PID) with impaired antibody production (see section 4.4). Secondary immunodeficiencies (SID) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either PROVEN SPECIFIC ANTIBODY FAILURE (PSAF)* or serum IgG level of <4 g/l. *PSAF = failure to mount at least a 2-fold rise in IgG antibody titre to pneumococcal polysaccharide and polypeptide antigen vaccines 3 Immunomodulation in adults, and children and adolescents (0-18 years) in: Primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count. Guillain Barré syndrome. Kawasaki disease (in conjunction with acetylsalicylic acid; see 4.2). Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Multifocal Motor Neuropathy (MMN). 4. Læs hele dokumentet